Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 30.69 CNY 0.39%
Market Cap: 5.4B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chengdu Easton Biopharmaceuticals Co Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Common Stock
ÂĄ120.1m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Common Stock
ÂĄ52k
CAGR 3-Years
0%
CAGR 5-Years
120%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Common Stock
ÂĄ603.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
14%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Common Stock
ÂĄ6.4B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Common Stock
ÂĄ1.8B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Common Stock
ÂĄ401m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chengdu Easton Biopharmaceuticals Co Ltd
Glance View

Market Cap
5.4B CNY
Industry
Pharmaceuticals

Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan and currently employs 1,188 full-time employees. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.

Intrinsic Value
50.9 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Common Stock?
Common Stock
120.1m CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Common Stock amounts to 120.1m CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
6%

Over the last year, the Common Stock growth was 0%.

Back to Top